Related Experiment Video

Updated: May 18, 2026

Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity
09:00

Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity

Published on: December 31, 2015

Targeting ILK and β4 integrin abrogates the invasive potential of ovarian cancer

Yoon Pyo Choi1, Baek Gil Kim, Ming-Qing Gao

  • 1BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.

Biochemical and Biophysical Research Communications
|October 3, 2012
PubMed

Insights

Targeting beta4 integrin and integrin-linked kinase (ILK) shows promise in ovarian cancer treatment. Depleting these molecules suppresses tumor growth, invasion, and metastasis, offering a potential new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Integrins and integrin-linked kinase (ILK) are crucial for cancer cell interactions with the extracellular matrix and oncogenic signaling.
  • Their roles in ovarian cancer progression and metastasis are significant, making them potential therapeutic targets.

Purpose of the Study:

  • To investigate the antitumoral effects of depleting beta1 and beta4 integrin, and ILK, individually and in combination, in ovarian cancer.
  • To assess the impact of these depletions on tumor aggressiveness and invasive potential.

Main Methods:

  • Immunohistochemistry was used to analyze beta1, beta4 integrin, and ILK expression in 196 ovarian cancer tissues.
  • Ovarian cancer cells were treated with shRNAs to deplete target molecules, followed by Western blot, RT-PCR, proliferation, migration, invasion, Rac1 activity, and xenograft assays.

Main Results:

  • Overexpression of beta4 integrin and ILK correlated with increased tumor aggressiveness in human ovarian cancer specimens.
  • Depletion of beta4 integrin and/or ILK significantly suppressed ovarian cancer cell proliferation, migration, invasion, and in vivo xenograft formation.
  • Combined depletion of beta4 integrin and ILK inhibited downstream signaling pathways (p-Akt, p-Erk1/2), Rac1 activation, reduced MMP-2/MMP-9 expression, and increased caspase-3 expression.

Conclusions:

  • Targeting beta4 integrin in combination with ILK can reverse the latent tumorigenic potential of ovarian cancer.
  • This combination therapy effectively abrogates the invasive potential of ovarian cancer, presenting a promising therapeutic strategy.

More Related Videos

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However, invadopodia can...